Anacor To Present Data From Long-Term Safety Study Of Crisaborole Topical Ointment, 2% In Patients With Mild-To-Moderate Atopic Dermatitis At Upcoming Medical Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced today that it will present data from the long-term safety study of crisaborole topical ointment, 2% in children and adults with mild-to-moderate atopic dermatitis at the Winter Clinical Dermatology Conference, being held in Koloa, Hawaii from January 15-20, 2016.

MORE ON THIS TOPIC